BioNTech Deal History & Licensing Activity
BioNTech is a large biotech headquartered in Germany. Over the past three years, BioNTech has been involved in 16 licensing and acquisition transactions, with a primary focus on Bispecific Antibodies (14 deals). The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
1
Active Trials
50
Top Modality
Bispecific Antibodies
Focus Area
Solid Tumors
BioNTech Recent Deal Activity
Licensing, acquisition, and partnership transactions involving BioNTech in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| MUC16-tinib | Boehringer Ingelheim | Bispecific Antibodies | Discovery | acquisition | Dec 2025 |
| SIRPα-101 | Vertex | Mab | Approved | option | Aug 2025 |
| solid tumors | BMS | Tce Gpcr | Phase 2 | license | Jul 2025 |
BioNTech Pipeline Focus
Therapeutic areas and modalities where BioNTech is most active based on deal history and clinical trial data.
Therapeutic Areas
BioNTech Strategic Signals
Key indicators of BioNTech's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
BioNTech Clinical Pipeline
BioNTech has 50 active clinical trials across 3 development phases.
23
Phase 1
15
Phase 2
12
Phase 3
See How Your Asset Matches BioNTech's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Mab Benchmarks
Upfront, milestone, and royalty benchmarks for mab deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About BioNTech Licensing & Deal Activity
BioNTech is a large biotech company based in Germany that has been actively engaged in licensing transactions across the biopharma landscape. With 16 deals over the past three years, BioNTech ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for BioNTech include Solid Tumors (28 deals and trials), Oncology (13 deals and trials), Option Deals (10 deals and trials), and Infectious (8 deals and trials). In terms of modality, BioNTech has shown particular interest in bispecific antibodies, mab, tce gpcr.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for BioNTech and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against BioNTech's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.